m6A RNA methylation regulators correlate with malignant progression and have potential predictive values in clear cell renal cell carcinoma.
Adenosine
/ metabolism
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
/ genetics
Carcinoma, Renal Cell
/ diagnosis
Cohort Studies
Disease Progression
Female
Gene Expression Regulation, Neoplastic
Humans
Kidney Neoplasms
/ diagnosis
Male
Methylation
/ drug effects
Methyltransferases
/ genetics
Middle Aged
Predictive Value of Tests
Prognosis
RNA Processing, Post-Transcriptional
/ drug effects
Survival Analysis
Transcriptome
Clear cell renal cell carcinoma
Consensus clustering
Prognosis
Progression
m6A RNA methylation
Journal
Experimental cell research
ISSN: 1090-2422
Titre abrégé: Exp Cell Res
Pays: United States
ID NLM: 0373226
Informations de publication
Date de publication:
01 07 2020
01 07 2020
Historique:
received:
12
12
2019
revised:
14
04
2020
accepted:
16
04
2020
pubmed:
26
4
2020
medline:
31
12
2020
entrez:
26
4
2020
Statut:
ppublish
Résumé
N6-methyladenosine (m6A) has been reported to be involved in several biological processes in tumors. In this study, we found that most of the m6A RNA methylation regulators were not only differentially expressed between clear cell renal cell carcinoma (ccRCC) and normal but also among ccRCC stratified by different clinicopathologic characters. Two ccRCC subgroups, cluster 1 and 2, were identified using consensus clustering based on the expression of m6A methylation regulators. Although no obvious differences were observed between two subgroups regarding clinicopathologic characters, except gender, patients in cluster 1 had a relatively more favorable survival rate than cluster 2. Moreover, we established a risk signature with two m6A methylation regulators, METTL3 and METTL14, which was not only of great value for prognosis prediction but also closely associated with clinicopathological features. In conclusion, m6A RNA methylation regulators play an important role in ccRCC progression and are potentially favorable for prognostic stratification.
Identifiants
pubmed: 32333907
pii: S0014-4827(20)30237-8
doi: 10.1016/j.yexcr.2020.112015
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
METTL14 protein, human
EC 2.1.1.-
Methyltransferases
EC 2.1.1.-
METTL3 protein, human
EC 2.1.1.62
Adenosine
K72T3FS567
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
112015Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare no conflict of interest.